NASDAQ:LQDA
Liquidia (LQDA)
Financials 
Technical Analysis 
Jul 24, 2026, 12:00 amThis summary was created by AI, based on 2 opinions in the last 12 months.
Liquidia (LQDA) operates in the pulmonary arterial hypertension (PAH) market, which has a significant addressable market estimated at $5 billion. Analysts believe that Liquidia's offering has competitive advantages over United Therapeutics, particularly in the efficacy of its drug, suggesting that it is gaining market share. Despite ongoing litigation with United concerning a drug, experts remain optimistic about Liquidia, with one analyst even transitioning investments from United to Liquidia. The projected earnings multiples indicate that Liquidia trades at a premium valuation of 10x its anticipated 2028 price-to-earnings ratio, which some analysts deem expensive for a potential blockbuster drug. Price targets provided by analysts show variance, with estimates set at $74.25 and $53.75, further sparking interest in the stock among investors looking for high-growth opportunities.
A small company involved in a rare lung disease, PAH. He made money off a similar situation in United Therapeutics, but LQDA has a better drug that is taking share from UT. So, he switched horses.
(Analysts’ price target is $53.75)
Gordon Reid- «
- ‹
- 1
- ›
- »
Popular Articles
Liquidia (LQDA) Frequently Asked Questions
What is Liquidia stock symbol?
Liquidia is a American stock, trading under the symbol LQDA (previously LQDA-Q on Stockchase) on the NASDAQ (LQDA). It is usually referred to as NASDAQ:LQDA or LQDA
Is Liquidia a buy or a sell?
In the last year, 2 stock analysts issued a Buy, Sell, or Hold rating on LQDA (previously LQDA-Q on Stockchase). 2 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is TOP PICK. Read the latest stock experts' ratings for Liquidia.
Is Liquidia a good investment or a top pick?
Liquidia was recommended as a Top Pick by Julien Nono-Womdim on 2026-07-21. Read the latest stock experts ratings for Liquidia.
Why is Liquidia stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Liquidia.
Is Liquidia worth watching?
Liquidia is covered by Stockchase experts and is worth watching.
What is Liquidia stock price?
On 2026-07-24, Liquidia (LQDA) stock closed at a price of $86.22.
The addressable market is $5 billion. LQDA has a superior offering to United Therapeutics. Trades at 10x 2028 PE, which is expensive for a blockbuster drug. They are in a lawsuit with United over a drug, but despite that, LQDA is a top pick.
(Analysts’ price target is $74.25)